Novel radiopharmaceuticals for molecular imaging of renal cell carcinoma
- Author(s)
- Weindler, J; Ali, M; Udovicich, C; Hofman, MS; Siva, S;
- Details
- Publication Year 2025,Volume 4,Issue #1,Page e000645
- Journal Title
- BMJ Oncology
- Publication Type
- Review
- Abstract
- Conventional diagnostic strategies for imaging patients with renal cell carcinoma (RCC) have predominantly relied on ultrasonography, CT and MRI. However, a paradigm shift is underway with the emergence of several new radiotracers for molecular imaging. Carbonic anhydrase IX (CA-IX) imaging and sestamibi imaging can assist with identifying malignant renal tumours, whereas fluorodeoxyglucose, prostate-specific membrane antigen and CA-IX tracers can give guidance for diagnosis and staging of RCC. These tracers can assist in enabling better decision-making by minimising overtreatment of renal masses with biopsy, better selecting patients for curative-intented management and optimising treatment for patients with oligo-metastatic disease, among other emerging indications. However, none of them is yet recommended as a standard clinical diagnostic procedure. In this review, we investigate the latest developments in molecular imaging for detecting and staging RCC, aiming to advance precision diagnosis and improve patient outcomes.
- Publisher
- BMJ
- Keywords
- Medical oncology; Radiotherapy; Renal cancer
- Department(s)
- Cancer Imaging; Radiation Oncology
- Publisher's Version
- https://doi.org/10.1136/bmjonc-2024-000645
- Open Access at Publisher's Site
https://doi.org/10.1136/bmjonc-2024-000645- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-09-16 11:53:38
Last Modified: 2025-09-16 11:58:20